Partnership Acceleration Biofidelity's Aspyre-Lung and Aspyre Clinical Test are already being integrated into CRO and clinical trial workflows (notably the CellCarta collaboration), signaling a ready-made channel to co-sell lung genomics to pharma, contract testing labs, and trial sponsors worldwide.

US Market Entry With a CLIA-certified US lab footprint in North Carolina and recent US launches, Biofidelity is well positioned to target US hospital systems, cancer centers, and CRO networks for lung cancer genomics and liquid biopsy assays, leveraging regulatory-ready offerings to accelerate adoption.

Lung Genomics Demand Focusing on Aspyre-Lung and lung cancer precision medicine aligns with growing demand for liquid biopsy and genomic-informed oncology, presenting opportunities to upsell to oncology clinics, pathology labs, and academic centers across multiple geographies.

Growth Capital Readiness Surplus funding and a scalable genomics platform give Biofidelity an opportunity to expand via distributor partnerships, regional sales reps, and joint ventures with CROs and biotechs to grow revenue beyond the current mid-market range.

Compliance as Differentiator Regulatory and data-security credentials, including GDPR compliance, position Biofidelity as a trusted partner for patient genomic data—an important differentiator when engaging hospitals, research institutes, and CROs handling sensitive information.